Human milk biomonitoring data: Interpretation and risk assessment issues

Journal of Toxicology and Environmental Health - Part A

Volumn 68, Issue 20, 2005, Pages 1713-1769

  LaKind, Judy S ^a,b   Brent, Robert L ^c   Dourson, Michael L ^d   Kacew, Sam ^e   Koren, Gideon ^f   Sonawane, Babasaheb ^g   Tarzian, Anita J ^h,i,j   Uhl, Kathleen ^k  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b LaKind Associates LLC   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Toxicology Excellence for Risk Assessment   (United States)

^e UNIVERSITY OF OTTAWA   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^h Ethics and Research Consultant   (United States)

ⁱ UNIVERSITY OF MARYLAND SCHOOL OF LAW   (United States)

^j UNIVERSITY OF MARYLAND SCHOOL OF NURSING   (United States)

^k CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BARIUM; DICAMBA; ENVIRONMENTAL CHEMICAL; MERCURY; PENTACHLOROPHENOL; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER;

ARTIFICIAL MILK; BENEFICENCE; BIOLOGICAL MONITORING; BREAST FEEDING; BREAST MILK; CONFERENCE PAPER; DOSE RESPONSE; ENVIRONMENTAL EXPOSURE; ETHICS; HEALTH HAZARD; HUMAN; INFORMATION PROCESSING; LACTATION; LATENT PERIOD; MEDICAL INFORMATION; MEDICAL RESEARCH; MOTHER CHILD RELATION; NONHUMAN; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TOXICOKINETICS; ADULT; CHEMISTRY; ENVIRONMENTAL MONITORING; EPIDEMIOLOGY; FEMALE; INFANT; INFANT WELFARE; METHODOLOGY; NEWBORN; POLLUTANT; REPRODUCIBILITY; REVIEW;

ADULT; ENVIRONMENTAL MONITORING; ENVIRONMENTAL POLLUTANTS; EPIDEMIOLOGIC STUDIES; FEMALE; HUMANS; INFANT; INFANT WELFARE; INFANT, NEWBORN; MERCURY; MILK, HUMAN; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; RISK ASSESSMENT;

EID: 26944468695     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287390500225724     Document Type: Conference Paper

References (134)

1. Abadin, H. G., Hibbs, B. F., and Pohl, H. R. 1997. Breast-feeding exposure of infants to cadmium, lead, and mercury: A public health viewpoint. Toxicol. Ind. Health. 13:495-517.
2. Agency for Toxic Substances and Disease Registry. 1999. Toxicological profile for mercury. Available at http:/ /www.atsdr.cdc.gov/toxprofiles/tp46. html.
3. Ahmad, S. R. 2003. Adverse drug event monitoring at the Food and Drug Administration. J. Gen. Intern. Med. 18:57-60.
4. Almenoff, J. S., DuMouchel, W., Kindman, L. A., Yang, X., and Fram, D. 2003. Disproportionality analysis using empirical Bayes data mining: A tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol. Drug Safety. 12:517-521.
5. American Academy of Pediatrics 1997. Policy statement: Breastfeeding and the use of human milk. Pediatrics 100:1035-1039.
6. American Academy of Pediatrics 2005. Breastfeeding and the use of human milk. American Academy of Pediatrics Work Group on Breastfeeding. Pediatrics 115:496-506.
7. Barnes, D. G., and Dourson, M. L. 1988. Reference dose (RfD): Description and use in health risk assessments. Regul. Toxicol. Pharmacol. 8:471-486.
8. Bates, N., Edwards, J. N., Roper, J., and Volans, G. N. 1997. Paediatric toxicology: Handbook of poisoning in children. New York: Grove.
9. Blatt, J., Van Le, L., Weiner, T., and Sailor, S. 2003. Ovarian carcinoma in adolescent with transgenerational exposure to DES. J. Pediatr. Hematol. / Oncol 25:635.
10. Bryant, A. E., III, and Dreifuss, F. E. 1996. Valproic acid hepatic fatalities, III. U.S. experience since 1986. Neurology 46:465-469.
11. Bucalossi, P., and Veronesi, U. 1957. Some observations on cancer of the breast in mothers and daughters. Br. J. Cancer. 11:337-347.
12. Centers for Disease Control and Prevention. 2004. DES third generation website. Available at http:// www.cdc.gov/des/consumers/third/index.html.
13. Chang, L. W. 1984. Developmental toxicology of methylmercury. In Toxicology and the newborn, eds. S. Kacew, and M. J. Reasor, pp. 173-197. Amsterdam: Elsevier Science.
14. Chang, L. W., and Sprecher, J. A. 1976. Degenerative changes in the neonatal kidney following in utero exposure to methylmercury. Environ. Res. 11:392-406.
15. Charnley, G., and Patterson, J. 2003. Review of procedures for protecting human subjects in recent clinical studies of pesticides. Regul. Toxicol. Pharmacol. 38:210-223.
16. Clewell, R. A., and Gearhart, J. M. 2002. Pharmacokinetics of toxic chemicals in breast milk: Use of PBPK models to predict infant exposure. Environ. Health Perspect. 110:A333-337.
17. Clewell, H. J., Teeguarden, J., McDonald, T., Sarangapani, R., Lawrence, G., Covington, T., Gentry, R., and Shipp, A. 2002. Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Crit. Rev. Toxicol. 32:329-389.
18. Code of Federal Regulations. 2004a. CFR 201.57 8).
19. Code of Federal Regulations. 2004b. CFR 314,80 and CFR 600.80.
20. Corley, R. A, Mast, T. J, Carney, E. W., Rogers, J. M., and Daston, G. P. 2003. Evaluation of physiologically based models of pregnancy and lactation for their application in children's health risk assessments. Crit. Rev. Toxicol. 33:137-211.
21. Cote, C. J., Notterman, D. A., Karl, H. W., Weinberg, J. A., and McCloskey, C. 2000. Adverse sedation events in pediatrics: A critical incident analysis of contributing factors. Pediatrics 105:805-814.
22. Council for International Organizations of Medical Sciences. 2002. International ethical guidelines for biomedical research involving human subjects. : Geneva, Switzerland CIOMS.
23. Cresteil, T. 1998. Onset of xenobiotic metabolism in children: Toxicological implications. Food Addit. Contam. 15(suppl.):45-51.
24. Crom, W. R. 1994. Pharmacokinetics in the child. Environ. Health Perspect. 102 (suppl. 11)111-117.
25. Cunningham, A. S., Jeliffe, D. B., and Jeliffe, E. F. P. 1991. Breast-feeding and health in the 1980s: a global epidemiologic view. J. Pediatr. 118:659-666.
26. Dourson, M. L. 1994. Methods for establishing oral reference doses (RfDs). In Risk assessment of essential elements, eds. W. Mertz, C.O. Abernathy, and S.S. Olin, pp. 51-61. Washington, DC: ILSI Press.
27. Dourson, M. L., Knauf, L. A., and Swartout, J. C. 1992. On reference dose (RfD) and its underlying toxicity data base. Toxicol. Ind. Health. 8:171-189.
28. Drasch, G., Aigner, S., Roider, G., Staiger, F., and Lipowsky, G. 1998. Mercury in human colostrum and early breast milk. Its dependence on dental amalgam and other factors. J. Trace Elem. Med. Biol. 12:23-27.
29. Dreifuss, F. E., Santilli, N., Langer, D. H., Sweeney, K. P., Moline, K. A., and Menander, K. B. 1987. Valproic acid hepatic fatalities: A retrospective review. Neurology 37:379-385.
30. Drexler, H., and Schaller, K. H. 1998. The mercury concentration in breast milk resulting from amalgam fillings and dietary habits. Environ. Res. 77:124-129.
31. DuMouchel, W. 1999. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am. Stat. 53:177-190.
32. Eiholm, B. E., Olsson, S., Moore, N., and Waller, P. 2000. Spontaneous reporting systems outside the US. In Pharmacoepidemiology, 3rd ed, ed. B. L. Strom, pp. 175-192. West Sussex: John Wiley & Sons.
33. Ekbom, A., Hsieh, C.-C., Trichopoulos, D., Yen, Y.-Y., Petridou, E., and Adami, H.-O. 1993. Breast-feeding and breast cancer in the offspring. Br. J. Cancer. 67:842-845.
34. Evans, L. S., and Kleiman, M. B. 1986. Acidosis as a presenting feature of chloramphenicol toxicity. J. Pediatr. 108:475-477.
35. Farland, W., and Dourson, M. L. 1992. Noncancer health endpoints: Approaches to quantitative risk assessment. In Comparative environmental risk assessment, ed. R. Cothern, pp. 87-106. Boca Raton, FL: Lewis.
36. Freudenheim, J. L., Marshall, J. R., Graham, S., Laughlin, R., Vena, J. E., Bandera, E., Muti, P., Swanson, M., and Nemoto, T. 1994. Exposure to breastmilk in infancy and the risk of breast cancer. Epidemiology 5:324-331.
37. Gentry, R., Teeguarden, J., Sarangapani, R., Covington, T., Lawrence, G., McDonald, T., Shipp, A., and Clewell, H. 2002. Evaluation of the potential impact of age and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol. Sci. 66 (1-S):abstr. 251).
38. Ginsberg, G., Hattis, D., Russ, A., and Sonawane, B. 2004. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: Implications for assessing children's risks from environmental agents. J. Toxicol. Environ. Health A 67:297-329.
39. Ginsberg, G., Hattis, D., Sonawane, B., Russ, A., Banati, P., Kozlak, M., Smolenski, S., and Goble, R. 2002. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol. Sci. 66:185-200.
40. Goldman, L. R. 1998. Chemicals and children's environment: What we don't know about risks. Environ. Health Perspect. 106 (suppl. 3)875-880.
41. Goldman, S. A. 1998. Limitations and strengths of spontaneous reports data. Clin. Ther. 20 (suppl. C):C40-44.
42. Greatrer Boston Physicians for Social Responsibility. 2002. Why breast-feeding is still best for baby. Available at http://psr.igc.org/ BFeasyeng2pg.10.18.pdf.
43. Gundacker, C., Pietschnig, B., Wittmann, K. J., Lischka, A., Salzer, H., Hohenauer, L., and Schuster, E. 2002. Lead and mercury in breast milk. Pediatrics 110:873-878.
44. Haber, L. T., Dollarhide, J. S., Maier, A., and Dourson, M. L. 2001. Noncancer risk assessment: Principles and practice in environmental and occupational settings. In Patty's toxicology , 5th ed, eds. E. Bingham, B. Cohrssen, and C. H. Powell pp. 169-232 New York: John Wiley and Sons.
45. Haddad, S., Restieri, C., and Krishnan, K. 2001. Characterization of age-related changes in body weight and organ weights from birth to adolescence in humans. J. Toxicol. Environ. Health A 64:453-464.
46. A. G., Hartzema, M., Porta, and H. H.Tilson, 1998. Pharmacoepidemiology. An introduction, 3rd ed. Cincinnati, OH: Harvey Whitney.
47. Hattis, D., Goble, R., and Banati, P. 1999a. Distributions of individual susceptibility among humans for toxic effects. How much protection does the traditional tenfold factor provide for what fraction of which kinds of chemicals and effects? Ann. NY Acad. Sci. 895:286-316.
48. Hattis, D., Goble, R., Banati, P., and Burmaster, D. 1999b. Human interindividual variability in parameters related to health risks. Risk Anal. 19:705-719.
49. Hauben, M., and Zhou, X. 2003. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Safety 26:159-186.
50. Henderson, B. E., Powell, D., Rosario, I., Keys, C., Hanisch, R., Young, M., Casagrande, J., Gerkins, V., and Pike, M. C. 1974. An epidemiologic study of breast cancer. J. Natl. Cancer Inst. 53:609-614.
51. Hines, R. N., and McCarver, D. G. 2002. The ontogeny of human drug-metabolizing enzymes: Phase 1 oxidative enzymes. 1. Pharmacol. Exp. Ther. 300:355-360.
52. Hoover, S. M. 1999. Exposure to persistent organochlorines in Canadian breast milk: A probabilistic assessment. Risk Anal. 19:527-545.
53. International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 1996. Good clinical practice: Guidance for industry. Available at http://www.fda.gov/ cder/guidance/959fnl. pdf.
54. International Society for Pharmacoepidemiology. 1996. Guidelines for good epidemiology practices for drug, device, and vaccine research in the United States revised. Available at http://http://www.pharmacoepi.org/resources/ goodprac.cfm.
55. Ito, S., and Koren, G. 1994. A novel index for expressing exposure of the infant to drug in breast milk. Br. J. Clin. Pharm. 38:99-102.
56. Jason, J., Nieburg, P., and Marks, J. S. 1984. Mortality and infectious disease associated with infant feeding practices in developing countries. Pediatrics 74 (suppl.)702-727.
57. Kacew, S. 1992. General principles in pharmacology and toxicology applicable to children. In Similarities and differences between children and adults: Implications for risk assessment,, eds. P. S. Guzelian, C. J. Henry, and S. S. Olin, pp. 24-34. Washington, DC: ILSI Press.
58. Kedderis, G. L. 1997. Extrapolation of in vitro enzyme induction data to humans in vivo. Chem. Biol. Interact. 107:109-121.
59. Kennedy, D. L., Goldman, S. A., and Lillie, R. B. 2000. Spontaneous reporting in the United States. In Pharmacoepidemiology , 3rd ed, ed. B. L. Strom, pp. 151-174. West Sussex: John Wiley & Sons.
60. Khera, K. S., and Tabacova, S. A. 1973. Effects of methylmercuric chloride on the progeny of mice treated before or during gestation. Food Cosmet. Toxicol. 11:245-254.
61. Klassen, C. D. 2001. Casarett and Doull's toxicology: The basic science of poisons, 6th ed. New York: Mc Graw-Hill.
62. Kosuda, L.L., Hosseinzadeh, H., Greiner, D. L., and Bigazzi, P. E. 1994. Mercury-induced renal autoimmunity: experimental manipulations of "susceptible" and "resistant" rats. J. Toxicol. Environ. Health. 42:303-321.
63. Kreuzer, P. E., Csanády, G. A., Baur, C., Kessler, W., Päpke, O., Greim, H., and Filser, J. G. 1997. TCDD and congeners in infants. A toxicokinetic model of human lifetime body burden by TCDD with as special emphasis on its uptake by nutrition. Arch. Toxicol. 71:383-400.
64. Kreuzer, P. E., Päpke, O., Baur, C., and Filser, J. G. 1993. Pharmacokinetic modelling of the body burden of 2,3,7,8-tetrachlorodibenzo-p- dioxin in man over the entire lifetime validated by measured data. Fundam. Clin. Pharmacol. 7:368.
65. Krishnan, K., and Andersen, M. E. 1994. Physiologically based pharmacokinetic modeling in toxicology. In Principles and methods of toxicology, 3rd ed, ed. A. Wallace Hayes, pp. 149-183. New York: Raven Press.
66. LaKind, J. S. 2002. Technical Workshop on Human Milk Surveillance and Research on Environmental Chemicals in the United States. J. Toxicol. Environ. Health A 65:1829-1935.
67. LaKind, J. S., Berlin, C. M., Park, C. N., Naiman, D. Q., and Gudka, N. J. 2000. Methodology for characterizing distributions of incremental body burdens of 2,3,7,8-TCDD and DDE from breast milk in North American nursing infants. J. Toxicol. Environ. Health A 60:101-135.
68. LaKind, J. S., Berlin, C., and Naiman, D. Q. 2001. Infant exposure to chemicals in breast milk in the United States: What we need to learn from a breast milk monitoring program. Environ. Health Perspect. 109:75-88.
69. Landrigan, P. J., Sonawane, B., Mattison, D., McCaully, M., and Garg, A. 2002. Chemical contaminants in breast milk and their impacts on children's health: An overview. Environ. Health Perspect. 110:A313.
70. Lawrence, R. A., and Lawrence, R. M. 1999. Breastfeeding: A guide for the medical profession, 5th ed. St. Louis, MO: Mosby.
71. Lindquis, T. M., and Edwards, I. R. 2001. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center. J. Rheumatol. 28:1180-1187.
72. Lorber, M., and Phillips, L. 2002. Infant exposure to dioxin-like compounds in breast milk. Environ Health Perspect 110:A325-A332.
73. Lovelady, C. A., Dewey, K. D., Picciano, M. F., and Dermer, A. 2002. Guidelines for collection of human milk samples for monitoring and research of environmental chemicals. J. Toxicol. Environ. Health A 65:1881-1892.
74. Makris, S., Raffaele, K., Sette, W., and Seed, J. 1998. A retrospective analysis of twelve developmental neurotoxicity studies submitted to the USEPA Office of Prevention, Pesticides, and Toxic Substances (OPPTS). Draft 11/12/98. Available at http://www.epa.gov/scipoly/sap/1998/december/neuro.pdf.
75. Mattsson, J. L., Maurissen, J. P. J., Nolan, R. J., and Brzak, K. A. 2000. Lack of differential sensitivity to cholinesterase inhibition in fetuses and neonates compared to dams treated perinatally with chlorpyrifos. Toxicol. Sci. 53:438-446.
76. McCarver, D. G., and Hines, R. N. 2002. The ontogeny of human drug-metabolizing enzymes: Phase II conjugation enzymes and regulatory mechanisms. J. Pharmacol. Exp. Ther. 300:361-366.
77. Moser, V. C., and Padilla, S. 1998. Age- and gender-related differences in the time course of behavioral and biochemical effects produced by oral chlorpyrifos in rats. Toxicol. Appl. Pharmacol. 149:107-119.
78. Mulhall, A., deLouvois, J., and Hurley, R. 1983. Chloramphenicol toxicity in neonates: Its incidence and prevention. Br. Med. J. 287:1424-1427.
79. National Academy of Sciences 1983. Risk assessment in the federal government: Managing the process. Washington, DC: National Academy Press.
80. National Academy of Sciences 1994. Science and judgment in risk assessment. Washington, DC: National Academy Press.
81. National Bioethics Advisory Commission. 1999. Research involving human biological materials: Ethical issues and policy guidance vol. I. Rockville, MD. August. Available at http://www.ntis.gov.
82. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. 1979. The Belmont report, Ethical principles and guidelines for the protection of human subjects of research. Washington, DC: Department of Health, Education, and Welfare. April.
83. National Research Council 1993. Pesticides in the diets of infants and children. Washington, DC: National Academy Press.
84. National Research Council 2000. Toxicological effects of methyl mercury. Washington, DC: National Academy Press.
85. Nestlé. 2004. Nestlébaby feeding guide. Available at http://www.nestle.ca/NR/rdonlyres/5B954F63-8A34-414C-AB82-BD0DCBABBC4B/0/ ENG_chart.pdf.
86. Newton, N. 1971. Psychological differences between breast and bottle feeding. Am. J. Clin. Nutr. 24:993-1004.
87. Norén, K., and Meironyté, D. 2000. Certain organochlorine and organobromine contaminants in Swedish human milk in perspective of past 20-30 years. Chemosphere 40:1111-1123.
88. Olesen, C., Steffensen, F. H., Nielsen, G. L., de Jong-van den Berg, L., Olsen, J., Sorensen, H. T., and the Euromap, Group 1999. Drug use in first pregnancy and lactation: A population-based survey among Danish women. Eur. J. Clin. Pharmacol. 55:139-144.
89. Oskarsson, A., Schultz, A., Skerfving, S., Hallen, I. P., Ohlin, B., and Lagerkvist, B. J. 1996. Total and inorganic mercury in breast milk in relation to fish consumption and amalgam in lactating women. Arch. Environ. Health. 51:234-241.
90. Oskarsson, A., Palminger, H. I., Sundberg, J., and Petersson, G. K. 1998. Risk assessment in relation to neonatal metal exposure. Analyst 123:19-23.
91. Pelekis, M., Gephart, L. A., and Lerman, S. E. 2001. Physiological-model- based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds. Regul. Toxicol. Pharmacol. 33:12-20.
92. Piazza-Hepp, T. D., and Kennedy, D. L. 1995. Reporting of adverse events to MedWatch. Am. J. Health Syst. Pharm. 52:1436-1439.
93. Pope, C. N., and Liu, J. 1997. Age-related differences in sensitivity to organophosphorus pesticides. Environ. Toxicol. Pharmacol. 4:309-314.
94. Potischman, N., and Troisi, R. 1999. In-utero and early life exposures in relation to risk of breast cancer. Cancer Causes Control 10:561-573.
95. Price, K., Haddad, S., and Krishnan, K. 2003. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children. J. Toxicol. Environ. Health A. 66:417-433.
96. Ravitsky, V., Kahn, J., Chen, D. T., and Fernandez, C. V. 2004. Disclosing research results to participants in genetic research: Clarifying the debate.. Presentation made at the meeting of the American Society for Bioethics and Humanities. Philadelphia, PA. October.
97. Renwick, A. G. 1998. Toxicokinetics in infants and children in relation to the ADI and TDI. Food Addit. Contam. 15 (suppl.)S17-S35.
98. Renwick, A. G., and Lazarus, N. R. 1998. Human variability and noncancer risk assessment - An analysis of the default uncertainty factor. Regul. Toxicol. Pharmacol. 27(1 Pt. 1):3-20.
99. Renwick, A. G., Dorne, J. L., and Walton, K. 2000. An analysis of the need for an additional uncertainty factor for infants and children. Regul. Toxicol. Pharmacol. 31:286-296.
100. Rogan, W. J., Blanton, P. J., Portier, C. J., and Stallard, E. 1991. Should the presence of carcinogens discourage breast feeding? Regul. Toxicol. Pharmacol. 13:228-240.
101. Rohyans, J., Walson, P. D., Wood, G. A., and MacDonald, W. A. 1984. Mercury toxicity following methiolate ear irrigation. J. Pediatr. 104:311-313.
102. Ropeik, D. 2001. "Fear factor" in an age of terrorism. MSNBC Gee-Whiz Science. Available at http:// msnbc.msn.com/id/3077306/.
103. Ross, W. D. 1930. The right and the good. Oxford: Oxford University Press.
104. Sandborgh-Englund, G., Ask, K., Belfrage, E., and Ekstrand, J. 2001. Mercury exposure in utero and during infancy. J. Toxicol. Environ. Health A 63:317-320.
105. Sandman, P. M., and Lanard, J. 2003. "Fear is spreading faster than SARS" - And so it should!" April 28. Available at http://www.psandman. com/col/SARS-1.htm.
106. Scheuplein, R., Charnley, G., and Dourson, M. L. 2002. Differential sensitivity of children and adults to chemical toxicity: I. Biological basis. Regul. Toxicol. Pharmacol. 35:429-447.
107. Schreiber, J. S. 1993. Predicted infant exposure to tetrachloroethene in human breastmilk. Risk Anal. 13:515-524.
108. Shurdut, B. A., Barraj, L., and Francis, M. 1998. Aggregate exposures under the Food Quality Protection Act: An approach using chlorpyrifos. Regul. Toxicol. Pharmacol. 28:165-177.
109. Soldin, O. P. 2002. Proposed PBPKmodel to predict infant exposure to toxic chemicals in breast milk. Environ. Health Perspect. 110:. A663; author reply A663-664.
110. Strom, B. L. 2000. Pharmacoepidemiology , 3rd ed. West Sussex: John Wiley & Sons.
111. Szarfman, A., Machado, S. G., and O'Neill, R. T. 2002. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Safety 25:381-392.
112. Titus-Ernstoff, L., Egan, K. M., Newcomb, P. A., Baron, J. A., Stampfer, M., Greenberg, E. R., Cole, B. F., Ding, J., Willett, W., and Trichopoulos, D. 1998. Exposure to breast milk in infancy and adult breast cancer risk. J. Natl. Cancer Inst. 90:921-924.
113. Tokuhata, G. K. 1969. Morbidity and mortality among off-spring of breast cancer mothers. Am. J. Epidemiol. 89:19-153.
114. Toxicology Excellence for Risk Assessment. 2004. International Toxicity Estimates for Risk (ITER) database. Glossary. Available at www.tera. organization/iter.
115. U.S. Environmental Protection Agency 1989. Risk assessment guidance for Superfund. Vol. I Human health evaluation manual (Part A). Interim final EPA/540/1-89/002. Washington, DC: Office of Emergency and Remedial Response.
116. U.S. Environmental Protection Agency. 1998. Health effects test guideline OPPTS 870.3800 Reproduction and fertility effects. EPA 712-C-98-208. Available at http://www.epa.gov/opptsfrs/O PPTS_Harmonized/ 870_Health_Effects_Test_Guidelines/Series/870-3800.pdf.
117. U.S. Environmental Protection Agency 2002. A review of the reference dose (RfD) and reference concentration (RfC) processes. Risk Assessment Forum.. EPA/630/P-02/002F.
118. U.S. Environmental Protection Agency 2003. Draft final guidelines for carcinogen risk assessment. External review draft. Washington, DC: Risk Assessment Forum. February.
119. U.S. Environmental Protection Agency. 2004. Integrated risk information system (IRIS). Office of Research and Development. Available at www.epa.gov/iris.
120. U.S. Environmental Protection Agency. 2005. Integrated risk information system (IRIS). Glossary. Office of Research and Development. Available at www.epa.gov/iris.
121. U.S. Food and Drug Administration. 1995. ICH document E1A. The extent of population exposure to assess clinical safety: For drugs intended for long-term treatment of non-life-threatening conditions. Available at http://www.fda.gov/ cder/guidance/index.htm.
122. U.S. Food and Drug Administration. 2004a. Draft guidance for industry - Premarketing risk assessment. Posted 5/4/04. Available at http://www.fda.gov/ cder/guidance/index.htm.
123. U.S. Food and Drug Administration. 2004b. Draft guidance for industry - Good pharmacovigilance practices and pharmacoepidemiologic assessment. Posted 5/4/04. Available at http://www.fda.gov/cder/ guidance/index.htm.
124. U.S. Food and Drug Administration. 2005. Guidance for industry clinical lactation studies - Study design, data analysis, and recommendations for labeling. Draft Guidance. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) and Center for Biologies Evaluation and Research (CBER). February. Available at http://www.fda.gov/cder/ guidance/index.htm.
125. Vest, M. F. 1965. The development of conjugation mechanisms and drug toxicity in the newborn. Biol. Neonate. 8:258-266.
126. Vimy, M. J., Hooper, D. E., King, W. W., and Lorscheider, F. L. 1997. Mercury from maternal "silver" tooth fillings in sheep and human breast milk. A source of neonatal exposure. Biol. Trace Elem. Res. 56:143-152.
127. Weiss, H. A., Potischman, N. A., Brinton, L. A., Brogan, D., Coates, R. J., Gammon, M. D., Malone, K. E., and Schoenberg, J. B. 1997. Prenatal and perinatal risk factors for breast cancer in young women. Epidemiology 8:181-187.
128. World Health Organization 1988. Assessment of health risks in infants associated with exposure to PCBs, PCDDs and PCDFs in breast milk. : WHO. Report on a WHO Working Group. Copenhagen: WHO.
129. World Health Organization 1989. World Health Organization environmental health 34. Levels of PCBs, PCDDs and PCDFs in breast milk, ed. E. J. Yrjanheikki Copenhagen, Denmark: WHO.
130. World Health Organization. 1998. GEMS/Food International Survey: Infant exposure to certain organochlorine contaminants from breast milk - A risk assessment, eds. D Schutz, Moy G. G., and F. K. Kaferstein. WHO Food Safety Unit, Programme of Food Safety and Food Aid. Geneva, Switzerland WHO/FSF/FOS/98.4.
131. World Medical Association. 2000 Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964; amended by the 29th World Medical Assembly, Tokyo, Japan, October 1975, the 35th World Medical Assembly, Venice, Italy, October 1983, the 41st World Medical Assembly, Hong Kong, September 1989, the 48th General Assembly, Somerset West, Republic of South Africa, October 1996, and the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000.http:// www.wma.net/e/policy/b3.htm.
132. Yang, J., Jiang, Z., Wang, Y., Qureshi, I. A., and Wu, X. D. 1997. Maternal-fetal transfer of metallic mercury via the placenta and milk. Ann. Clin. Lab. Sci. 27:135-141.
133. Zheng, Q., Olivier, K., Won, Y. K., and Pope, C. N. 2000. Comparative cholinergic neurotoxicity of oral chlorpyrifos exposures in preweanling and adult rats. Toxicol. Sci. 55:124-132.
134. Zhou, W., Pool, V., Iskander, J. K., English-Bullard, R., Ball, R., Wise, R. P., Haber, P., Pless, R. P., Mootrey, G., Ellenberg, S. S., Braun, M. M., and Chen, R. T. 2003. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) - United States, 1991-2001. Morbid. Mortal. Weekly Rep. Surveill. Summ. 24 (52)1-24.